Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

Transthyretin Cardiac Amyloidosis a Common Cause of HF in Older Black Patients

News Daily News

Transthyretin Cardiac Amyloidosis a Common Cause of HF in Older Black Patients

September 12, 2025

TITRATE-HF: Use of GDMT for HF Is Getting Better but Still Not Ideal

News Conference News ESC Heart Failure 2025

TITRATE-HF: Use of GDMT for HF Is Getting Better but Still Not Ideal

May 21, 2025

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

News Conference News NY Valves 2024

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

Michael O'Riordan

June 12, 2024

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

Debating the Role of T-TEER in the Sickest Patients

News Conference News THT 2024

Debating the Role of T-TEER in the Sickest Patients

Michael O'Riordan

March 05, 2024

Poor Outcomes in HF Patients With Moderate Aortic Stenosis: Observational Data

News Daily News

Poor Outcomes in HF Patients With Moderate Aortic Stenosis: Observational Data

Michael O'Riordan

March 29, 2023

REDUCE LAP-HF II Subanalysis Makes the Case for Invasive Exercise Tests

News Conference News THT 2023

REDUCE LAP-HF II Subanalysis Makes the Case for Invasive Exercise Tests

Yael L. Maxwell

March 22, 2023

Heart Failure Care Has a Pipeline Problem: What’s the Fix?

News Features

Heart Failure Care Has a Pipeline Problem: What’s the Fix?

December 20, 2022

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

June 21, 2022

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

The Hunt for Protein Culprits in COVID-19’s Cardiac Complications

News Daily News

The Hunt for Protein Culprits in COVID-19’s Cardiac Complications

Michael O'Riordan

May 06, 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

News Conference News THT 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

February 07, 2022

Moderate Aortic Stenosis and HFrEF Combo Portends Poor Survival, Study Finds

News Daily News

Moderate Aortic Stenosis and HFrEF Combo Portends Poor Survival, Study Finds

June 03, 2021

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

News Daily News

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

July 29, 2019

Proportionate and Disproportionate MR: A ‘Framework’ for MitraClip and Medical Therapy

News Daily News

Proportionate and Disproportionate MR: A ‘Framework’ for MitraClip and Medical Therapy

May 09, 2019

Heart Failure Risk Following 'Silent' MI Warrants Scrutiny: ARIC Analysis

News Daily News

Heart Failure Risk Following 'Silent' MI Warrants Scrutiny: ARIC Analysis

January 08, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.